Progenity, Inc. Email Format
BiotechnologyCalifornia, United States51-200 Employees
Progenity, Inc. is a mid‑sized biotechnology company based in San Diego, California, focused on women’s health, gastrointestinal health, and oral biotherapeutics. It pursues an integrated molecular approach to develop diagnostic testing products and investigational ingestible devices intended to sample biological material and deliver therapies with precision. The company aims to improve disease diagnosis and enable localized treatment through targeted therapies. By combining diagnostic and delivery capabilities, Progenity seeks to address clinically meaningful needs in its core areas of focus. Its customers include healthcare providers and patients seeking advanced diagnostics and targeted gastrointestinal interventions supported by its products and devices. In February 2022, Progenity announced progress on the PGN-600 program, which involves an oral liquid formulation of tofacitinib delivered to the colon via its ingestible capsule platform for ulcerative colitis.